ArticleHeart rhythm O22025
Atrial fibrillation laser balloon ablation: Multicenter international study.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current and Emerging Energy Sources for Atrial Fibrillation Ablation: A Comparative Analysis of Clinical Efficacy, Safety, and Procedural Implementation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Durable pulmonary vein isolation (PVI) for atrial fibrillation (AF) remains challenging. The visually guided laser balloon (VGLB) is a unique single-shot technology designed to simplify PVI. Objective: This study aimed to assess the real-world safety and long-term effectiveness of the third-generation VGLB system for treating paroxysmal and persistent AF. Methods: This prospective, multicenter registry enrolled 427 patients undergoing VGLB-PVI. Safety was assessed in all patients, whereas the primary effectiveness endpoint (12-month freedom from AF) was analyzed in 392 patients who completed follow-up. Cox regression models were used to identify predictors of recurrence. Results: Acute PVI was achieved in all targeted veins. The system demonstrated a favorable safety profile; permanent phrenic nerve palsy occurred in 1 patient (0.2%). After a 3-month blanking period, the 12-month freedom from AF recurrence off antiarrhythmic drugs was 73.8%. This rate increased to 77.7% for procedures performed after the initial 15-case operator learning curve. Multivariate analysis identified procedures within the learning curve (hazard ratio [HR] 1.68), congestive heart failure (HR 2.04), and anatomic variants (HR 1.79) as independent predictors of recurrence. Conclusion: In this large, real-world registry, third-generation VGLB ablation is a safe and effective strategy for achieving long-term freedom from AF. Operator experience beyond the initial learning curve is a key determinant of success, confirming VGLB as a viable and effective PVI option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.